In comparison to our molecular analysis, Robertson et al. found 7.4% KRAS mutations (G12D) in a cohort of 54 intrahepatic cholangiocarcinomas, which were associated with a worse long-term overall survival [26]. This evidence concerns the gene KRAS and cholangiocarcinoma.